Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (67)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Van den Berg, L. H.
Right arrow Articles by Wokke, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van den Berg, L. H.
Right arrow Articles by Wokke, J. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol 121, Issue 3 421-428, Copyright © 1998 by Oxford University Press

ARTICLES

The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy

LH Van den Berg, H Franssen and JH Wokke
Department of Neurology, Rudolf Magnus Research School in the Neurosciences, University Hospital, Utrecht, The Netherlands.

We studied the long-term effect of intravenous immunoglobulin (IV Ig) treatment in seven patients with multifocal motor neuropathy. In six patients, treatment with a full IV Ig course (0.4 g/kg for 5 consecutive days) improved muscle strength but for not longer than 12 weeks. These patients received IV Ig maintenance treatment consisting of one infusion every week for 2-4 years. One patient in whom the effect of the initial full IV Ig treatment lasted for more than 1 year received incidental IV Ig treatment when muscle strength deteriorated. In all patients IV Ig treatment had a beneficial effect on most muscle groups during the follow-up period. However, in three of the seven patients muscle strength deteriorated during IV Ig maintenance treatment in four of the 28 muscle groups that had initially shown an improvement of muscle strength after the start of IV Ig treatment, and in two muscle groups with normal strength at the start of IV Ig treatment. The electrophysiological follow-up studies indicated that there was an improvement of conduction block, but also that there were new sites of conduction block and ongoing axonal degeneration during IV Ig maintenance treatment.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
Y A Rajabally
Multifocal motor neuropathy: review of a treatable immune mediated disorder
Postgrad. Med. J., June 1, 2008; 84(992): 287 - 292.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Slee, A. Selvan, and M. Donaghy
Multifocal motor neuropathy: The diagnostic spectrum and response to treatment
Neurology, October 23, 2007; 69(17): 1680 - 1687.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J T H Van Asseldonk, L H Van den Berg, S Kalmijn, R M Van den Berg-Vos, C H Polman, J H J Wokke, and H Franssen
Axon loss is an important determinant of weakness in multifocal motor neuropathy.
J. Neurol. Neurosurg. Psychiatry, June 1, 2006; 77(6): 743 - 747.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
A. Priori, B. Bossi, G. Ardolino, L. Bertolasi, M. Carpo, E. Nobile-Orazio, and S. Barbieri
Pathophysiological heterogeneity of conduction blocks in multifocal motor neuropathy
Brain, July 1, 2005; 128(7): 1642 - 1648.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J. T. H. Van Asseldonk, L. H. Van den Berg, S. Kalmijn, J. H. J. Wokke, and H. Franssen
Criteria for demyelination based on the maximum slowing due to axonal degeneration, determined after warming in water at 37{degrees}C: diagnostic yield in chronic inflammatory demyelinating polyneuropathy
Brain, April 1, 2005; 128(4): 880 - 891.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Vucic, K. R. Black, P. S. T. Chong, and D. Cros
Multifocal motor neuropathy: Decrease in conduction blocks and reinnervation with long-term IVIg
Neurology, October 12, 2004; 63(7): 1264 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J. T. H. Van Asseldonk, L. H. Van den Berg, R. M. Van den Berg-Vos, G. H. Wieneke, J. H. J. Wokke, and H. Franssen
Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness
Brain, January 1, 2003; 126(1): 186 - 198.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
R. M. Van den Berg-Vos, H. Franssen, J. H. J. Wokke, and L. H. V. d. Berg
Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment
Brain, August 1, 2002; 125(8): 1875 - 1886.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Visser, R. M. van den Berg-Vos, H. Franssen, L. H. van den Berg, O. J. Vogels, J. H.J. Wokke, J. M.B.V. de Jong, and M. de Visser
Mimic syndromes in sporadic cases of progressive spinal muscular atrophy
Neurology, June 11, 2002; 58(11): 1593 - 1596.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
L L Teunissen, H Franssen, J H J Wokke, Y van der Graaf, W H J P Linssen, J D Banga, D M Laman, and N C Notermans
Is cardiovascular disease a risk factor in the development of axonal polyneuropathy?
J. Neurol. Neurosurg. Psychiatry, May 1, 2002; 72(5): 590 - 595.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al.
Intravenous immunoglobulin in neurological disease: a specialist review
J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J.S. Katz, R.J. Barohn, S. Kojan, G.I. Wolfe, S.P. Nations, D.S. Saperstein, and A.A. Amato
Axonal multifocal motor neuropathy without conduction block or other features of demyelination
Neurology, February 26, 2002; 58(4): 615 - 620.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. H. Noseworthy, P. C. O'Brien, T. M. Petterson, J. Weis, L. Stevens, W. K. Peterson, D. Sneve, S. A. Cross, J. A. Leavitt, R. G. Auger, et al.
A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
Neurology, June 12, 2001; 56(11): 1514 - 1522.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J.-M. Leger, B. Chassande, L. Musset, V. Meininger, P. Bouche, and N. Baumann
Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double-blind, placebo-controlled study
Brain, January 1, 2001; 124(1): 145 - 153.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P.A. van Doorn and F.G.A. van der Meche
IVIg treatment improves multifocal motor neuropathy: Easy to start but difficult to stop
Neurology, November 14, 2000; 55(9): 1246 - 1247.
[Full Text] [PDF]

Home page
 NeurologyHome page
P. Federico, D.W. Zochodne, A.F. Hahn, W.F. Brown, and T. E. Feasby
Multifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebo-controlled study
Neurology, November 14, 2000; 55(9): 1256 - 1262.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. M. Van den Berg-Vos, L. H. Van den Berg, H. Franssen, P. A. Van Doorn, I. S. J. Merkies, and J. H. J. Wokke
Treatment of multifocal motor neuropathy with interferon-{beta}1A
Neurology, April 11, 2000; 54(7): 1518 - 1521.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
P. S. Sorensen
Intravenous Immunoglobulin Treatment in Neurologic Disorders: Yes
Arch Neurol, August 1, 1999; 56(8): 1025 - 1027.
[Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J. H J WOKKE and L. H VAN DEN BERG
New hope for patients with pure lower motor neuron syndromes
J. Neurol. Neurosurg. Psychiatry, July 1, 1999; 67(1): 6 - 6.
[Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.